— AstraZeneca Plc (NYSE: AZN) reported its third-quarter 2019 earnings of $0.23 per share and core earnings of $0.99 per share. This is compared to $0.45 per share expected.
— Total revenue increased by 20% to $6.41 billion versus $6.18 billion expected. This is driven by a 16% jump in product sales.
— Oncology sales jumped by 46% and respiratory sales grew by 15%. Biopharmaceuticals sales increased by 12% and new CVRM sales rose by 8% while sales in other medicines fell by 9%.
— Looking ahead into the full year 2019, the company reiterates its core earnings guidance in the range of $3.50 to $3.70 per share.
— The core operating profit for fiscal 2019 is predicted to increase ahead of product sales.
— For the full year, capital expenditure is anticipated to be broadly stable and restructuring expenses are targeted to reduce versus the prior-year.
Most Popular
KBH Earnings: KB Home Q1 profit drops on lower sales, misses estimates
Homebuilder KB Home (NYSE: KBH) on Monday announced financial results for the first quarter of 2025, reporting lower revenues and profit. The bottom line fell short of expectations. First-quarter net
Can Nike (NKE) achieve sustainable growth under new leadership?
Nike, Inc. (NYSE: NKE) is banking on innovations in its product portfolio and improvements in the operating environment to regain strength, while it continues to grapple with multiple headwinds affecting
Here’s how Lennar (LEN) is navigating a challenging macroeconomic environment
Shares of Lennar Corporation (NYSE: LEN) gained over 1% on Monday. The stock has dropped 11% over the past three months. The homebuilder grew its revenues in the first quarter
